Seoulin Bioscience Co.Ltd Total Assets
Seoulin Bioscience Co.Ltd total assets. Based on the latest financial reports, Seoulin Bioscience Co.Ltd (038070) holds total assets worth ₩118.80 Billion KRW (≈ $80.51 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 038070 market cap for the company's overall valuation and market capitalisation.
Total Assets of Seoulin Bioscience Co.Ltd (2013–2025)
Total assets of Seoulin Bioscience Co.Ltd from 2013 to 2025. This chart illustrates how Seoulin Bioscience Co.Ltd's total assets have evolved over time, based on quarterly financial data. See 038070 stock price and chart for real-time trading data and today's change.
Seoulin Bioscience Co.Ltd - Asset Composition Analysis
Seoulin Bioscience Co.Ltd Total Assets Breakdown (December 2025)
Seoulin Bioscience Co.Ltd total assets breakdown as of December 2025. Seoulin Bioscience Co.Ltd's total assets of ₩118.80 Billion consist of 60.6% current assets and 39.4% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 8.8% |
| Accounts Receivable | ₩8.12 Billion | 6.8% |
| Inventory | ₩24.72 Billion | 20.8% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩429.63 Million | 0.4% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Seoulin Bioscience Co.Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 038070 net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Seoulin Bioscience Co.Ltd's current assets represent 60.6% of total assets in 2025, an increase from 0.0% in 2013.
- Cash Position: Cash and equivalents constituted 8.8% of total assets in 2025, up from 6.4% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 20.8% of total assets.
Seoulin Bioscience Co.Ltd Competitors by Total Assets
Key competitors of Seoulin Bioscience Co.Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Seoulin Bioscience Co.Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.27 | 4.39 | 3.01 |
| Quick Ratio | 1.49 | 2.46 | 2.28 |
| Cash Ratio | 0.00 | 0.66 | 0.00 |
| Working Capital | ₩40.37 Billion | ₩46.21 Billion | ₩28.92 Billion |
Seoulin Bioscience Co.Ltd - Advanced Valuation Insights
This section examines the relationship between Seoulin Bioscience Co.Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.65 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 17.0% |
| Total Assets | ₩118.80 Billion |
| Market Capitalization | $21.44 Million USD |
Valuation Analysis
Below Book Valuation: The market values Seoulin Bioscience Co.Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Seoulin Bioscience Co.Ltd's assets grew by 17.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Seoulin Bioscience Co.Ltd (2013–2025)
The table below shows the annual total assets of Seoulin Bioscience Co.Ltd from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩118.80 Billion ≈ $80.51 Million |
+17.01% |
| 2024-12-31 | ₩101.52 Billion ≈ $68.80 Million |
-11.02% |
| 2023-12-31 | ₩114.10 Billion ≈ $77.32 Million |
-15.40% |
| 2022-12-31 | ₩134.87 Billion ≈ $91.40 Million |
-1.24% |
| 2021-12-31 | ₩136.57 Billion ≈ $92.55 Million |
+74.53% |
| 2020-12-31 | ₩78.25 Billion ≈ $53.03 Million |
-3.05% |
| 2019-12-31 | ₩80.71 Billion ≈ $54.69 Million |
+13.49% |
| 2018-12-31 | ₩71.11 Billion ≈ $48.19 Million |
+0.10% |
| 2017-12-31 | ₩71.04 Billion ≈ $48.14 Million |
+6.87% |
| 2016-12-31 | ₩66.47 Billion ≈ $45.05 Million |
+0.55% |
| 2015-12-31 | ₩66.10 Billion ≈ $44.80 Million |
+8.87% |
| 2014-12-31 | ₩60.72 Billion ≈ $41.15 Million |
+0.55% |
| 2013-12-31 | ₩60.39 Billion ≈ $40.92 Million |
-- |
About Seoulin Bioscience Co.Ltd
Seoulin Bioscience Co.,Ltd., a bio healthcare company, provides solutions in life sciences and healthcare primarily in South Korea. The company offers solutions for bio research and production; ecoTree, a SLB-120 instrument which produces slightly acidic electrolyzed water for used in food industry, living, and laboratory; plasma-based medical esthetics; miQ for the diagnosis of dementia; and fun… Read more